{
    "clinical_study": {
        "@rank": "136104", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Brexpiprazole", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Quetiapine extended release", 
                "arm_group_type": "Other", 
                "description": "Active Reference"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the efficacy and safety of brexpiprazole for the treatment of adults\n      experiencing an acute episode of schizophrenia."
        }, 
        "brief_title": "Brexpiprazole in Patients With Acute Schizophrenia", 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient has schizophrenia, diagnosed according to DSM-IV-TR\u2122 and confirmed by the\n             Mini International Neuropsychiatric Interview (MINI).\n\n          -  The patient has an acute exacerbation of psychotic symptoms and marked deterioration\n             of usual function.\n\n          -  The patient is willing to be hospitalised from the Screening Visit through Week 6.\n\n          -  The patient will benefit from hospitalisation or continued hospitalisation for\n             treatment of a current acute relapse of schizophrenia at study entry.\n\n          -  The patient has a history of relapse and/or exacerbation of symptoms when not\n             receiving antipsychotic treatment, excluding the current episode.\n\n          -  The patient agrees to protocol-defined use of effective contraception.\n\n        Exclusion Criteria:\n\n          -  The patient has a current Axis I diagnosis (DSM-IV-TR\u2122 criteria) other than\n             schizophrenia established as primary diagnosis.\n\n          -  The patient suffers from a current Axis II diagnosis (DSM-IV-TR\u2122 criteria).\n\n          -  The patient suffers from mental retardation, organic mental disorders, or mental\n             disorders due to a general medical condition (DSM-IV-TR\u2122 criteria).\n\n          -  The patient, in the opinion of the investigator or according to Columbia Suicide\n             Severity Rating Scale (C-SSRS), is at significant risk of suicide.\n\n          -  The patient has clinically significant tardive dyskinesia or severe akathisia at\n             enrolment.\n\n          -  The patient has a history of neuroleptic malignant syndrome.\n\n          -  The patient has any relevant medical history or current presence of systemic disease.\n\n          -  The patient has, at the Screening Visit an abnormal ECG or other abnormal ECG tests\n             that are, in the investigator's opinion, clinically significant.\n\n          -  The patient has a history of cancer, other than basal cell or Stage 1 squamous cell\n             carcinoma of the skin, that has not been in remission for >5 years prior to the first\n             dose of brexpiprazole.\n\n          -  The patient is, in the investigator's opinion, unlikely to comply with the protocol\n             or is unsuitable for any reason.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "465", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810380", 
            "org_study_id": "14644A", 
            "secondary_id": "2012-002252-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Once daily as tablets and capsules, orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Brexpiprazole", 
                "description": "Up to 4 mg/day, once daily, tablets, orally", 
                "intervention_name": "Brexpiprazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Quetiapine extended release", 
                "description": "Up to 800 mg/day, once daily, encapsulated tablets, orally", 
                "intervention_name": "Quetiapine extended release", 
                "intervention_type": "Drug", 
                "other_name": "Seroquel XL\u00ae/XR\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Quetiapine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Escondido", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92025"
                }, 
                "name": "US009"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Estonia: The State Agency of Medicine", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Poland: National Institute of Medicines", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Serbia: Medicines and Medical Devices Agency", 
                "Ukraine: State Pharmacological Center - Ministry of Health", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Positive and Negative Syndrome Scale (PANSS) total score", 
            "measure": "Change from baseline in efficacy using PANSS", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810380"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical Global Impression - Severity of Illness (CGI-S) score", 
                "measure": "Change from baseline in clinical global impression", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "Clinical Global Impression - Global Improvement (CGI-I) score", 
                "measure": "Improvement of clinical global impression", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "description": "PANSS Positive Subscale score", 
                "measure": "Change from baseline in psychotic symptoms", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "PANSS Negative Subscale score", 
                "measure": "Change from baseline in psychotic symptoms", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "PANSS Excited Component score", 
                "measure": "Change from baseline in psychotic symptoms", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "PANSS Marder Factor scores", 
                "measure": "Change from baseline in psychotic symptoms", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "Based on pre-specified reduction in PANSS total score or CGI-I score", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "Personal and Social Performance Scale (PSP) score", 
                "measure": "Change from baseline in personal and social performance", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "Number of adverse events", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 weeks and a safety follow-up by telephone contact or clinic visit after 30 days after the last dose of investigational medicinal product (IMP) for patients who do not enter the follow-up study 14644B"
            }, 
            {
                "description": "Columbia-Suicide Severity Rating Scale (C-SSRS) score", 
                "measure": "Risk of suicidality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 weeks"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}